These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 29478202

  • 21. AQP2: Mutations Associated with Congenital Nephrogenic Diabetes Insipidus and Regulation by Post-Translational Modifications and Protein-Protein Interactions.
    Gao C, Higgins PJ, Zhang W.
    Cells; 2020 Sep 26; 9(10):. PubMed ID: 32993088
    [Abstract] [Full Text] [Related]

  • 22. Lack of arginine vasopressin-induced phosphorylation of aquaporin-2 mutant AQP2-R254L explains dominant nephrogenic diabetes insipidus.
    de Mattia F, Savelkoul PJ, Kamsteeg EJ, Konings IB, van der Sluijs P, Mallmann R, Oksche A, Deen PM.
    J Am Soc Nephrol; 2005 Oct 26; 16(10):2872-80. PubMed ID: 16120822
    [Abstract] [Full Text] [Related]

  • 23. Stimulation of AQP2 membrane insertion in renal epithelial cells in vitro and in vivo by the cGMP phosphodiesterase inhibitor sildenafil citrate (Viagra).
    Bouley R, Pastor-Soler N, Cohen O, McLaughlin M, Breton S, Brown D.
    Am J Physiol Renal Physiol; 2005 Jun 26; 288(6):F1103-12. PubMed ID: 15644488
    [Abstract] [Full Text] [Related]

  • 24. Genetic forms of nephrogenic diabetes insipidus (NDI): Vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant).
    Bichet DG, Bockenhauer D.
    Best Pract Res Clin Endocrinol Metab; 2016 Mar 26; 30(2):263-76. PubMed ID: 27156763
    [Abstract] [Full Text] [Related]

  • 25. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists.
    Robben JH, Kortenoeven ML, Sze M, Yae C, Milligan G, Oorschot VM, Klumperman J, Knoers NV, Deen PM.
    Proc Natl Acad Sci U S A; 2009 Jul 21; 106(29):12195-200. PubMed ID: 19587238
    [Abstract] [Full Text] [Related]

  • 26. Disruption of prostaglandin E2 receptor EP4 impairs urinary concentration via decreasing aquaporin 2 in renal collecting ducts.
    Gao M, Cao R, Du S, Jia X, Zheng S, Huang S, Han Q, Liu J, Zhang X, Miao Y, Kang J, Gustafsson JÅ, Guan Y.
    Proc Natl Acad Sci U S A; 2015 Jul 07; 112(27):8397-402. PubMed ID: 26100911
    [Abstract] [Full Text] [Related]

  • 27. Molecular mechanisms and drug development in aquaporin water channel diseases: molecular mechanism of water channel aquaporin-2 trafficking.
    Noda Y, Sasaki S.
    J Pharmacol Sci; 2004 Nov 07; 96(3):249-54. PubMed ID: 15539762
    [Abstract] [Full Text] [Related]

  • 28. X-ray structure of human aquaporin 2 and its implications for nephrogenic diabetes insipidus and trafficking.
    Frick A, Eriksson UK, de Mattia F, Oberg F, Hedfalk K, Neutze R, de Grip WJ, Deen PM, Törnroth-Horsefield S.
    Proc Natl Acad Sci U S A; 2014 Apr 29; 111(17):6305-10. PubMed ID: 24733887
    [Abstract] [Full Text] [Related]

  • 29. Aliskiren increases aquaporin-2 expression and attenuates lithium-induced nephrogenic diabetes insipidus.
    Lin Y, Zhang T, Feng P, Qiu M, Liu Q, Li S, Zheng P, Kong Y, Levi M, Li C, Wang W.
    Am J Physiol Renal Physiol; 2017 Oct 01; 313(4):F914-F925. PubMed ID: 28228402
    [Abstract] [Full Text] [Related]

  • 30. Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus.
    Robben JH, Knoers NV, Deen PM.
    Am J Physiol Renal Physiol; 2006 Aug 01; 291(2):F257-70. PubMed ID: 16825342
    [Abstract] [Full Text] [Related]

  • 31. p.R254Q mutation in the aquaporin-2 water channel causing dominant nephrogenic diabetes insipidus is due to a lack of arginine vasopressin-induced phosphorylation.
    Savelkoul PJ, De Mattia F, Li Y, Kamsteeg EJ, Konings IB, van der Sluijs P, Deen PM.
    Hum Mutat; 2009 Oct 01; 30(10):E891-903. PubMed ID: 19585583
    [Abstract] [Full Text] [Related]

  • 32. Novel treatment for lithium-induced nephrogenic diabetes insipidus rat model using the Sendai-virus vector carrying aquaporin 2 gene.
    Suga H, Nagasaki H, Kondo TA, Okajima Y, Suzuki C, Ozaki N, Arima H, Yamamoto T, Ozaki N, Akai M, Sato A, Uozumi N, Inoue M, Hasegawa M, Oiso Y.
    Endocrinology; 2008 Nov 01; 149(11):5803-10. PubMed ID: 18653713
    [Abstract] [Full Text] [Related]

  • 33. Methyl-beta-cyclodextrin induces vasopressin-independent apical accumulation of aquaporin-2 in the isolated, perfused rat kidney.
    Russo LM, McKee M, Brown D.
    Am J Physiol Renal Physiol; 2006 Jul 01; 291(1):F246-53. PubMed ID: 16449354
    [Abstract] [Full Text] [Related]

  • 34. An AMPK activator as a therapeutic option for congenital nephrogenic diabetes insipidus.
    Klein JD, Khanna I, Pillarisetti R, Hagan RA, LaRocque LM, Rodriguez EL, Sands JM.
    JCI Insight; 2021 Apr 22; 6(8):. PubMed ID: 33724959
    [Abstract] [Full Text] [Related]

  • 35. Demonstration of the functional impact of vasopressin signaling in the thick ascending limb by a targeted transgenic rat approach.
    Mutig K, Borowski T, Boldt C, Borschewski A, Paliege A, Popova E, Bader M, Bachmann S.
    Am J Physiol Renal Physiol; 2016 Aug 01; 311(2):F411-23. PubMed ID: 27306979
    [Abstract] [Full Text] [Related]

  • 36. Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride.
    Bedford JJ, Weggery S, Ellis G, McDonald FJ, Joyce PR, Leader JP, Walker RJ.
    Clin J Am Soc Nephrol; 2008 Sep 01; 3(5):1324-31. PubMed ID: 18596116
    [Abstract] [Full Text] [Related]

  • 37. Tamoxifen attenuates development of lithium-induced nephrogenic diabetes insipidus in rats.
    Tingskov SJ, Hu S, Frøkiær J, Kwon TH, Wang W, Nørregaard R.
    Am J Physiol Renal Physiol; 2018 May 01; 314(5):F1020-F1025. PubMed ID: 29357422
    [Abstract] [Full Text] [Related]

  • 38. Treating lithium-induced nephrogenic diabetes insipidus with a COX-2 inhibitor improves polyuria via upregulation of AQP2 and NKCC2.
    Kim GH, Choi NW, Jung JY, Song JH, Lee CH, Kang CM, Knepper MA.
    Am J Physiol Renal Physiol; 2008 Apr 01; 294(4):F702-9. PubMed ID: 18216147
    [Abstract] [Full Text] [Related]

  • 39. Sildenafil for the Treatment of Congenital Nephrogenic Diabetes Insipidus.
    Assadi F, Sharbaf FG.
    Am J Nephrol; 2015 Apr 01; 42(1):65-9. PubMed ID: 26337818
    [Abstract] [Full Text] [Related]

  • 40. Loss of calcineurin Aalpha results in altered trafficking of AQP2 and in nephrogenic diabetes insipidus.
    Gooch JL, Guler RL, Barnes JL, Toro JJ.
    J Cell Sci; 2006 Jun 15; 119(Pt 12):2468-76. PubMed ID: 16735444
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.